Who are MW032's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DURVALUMAB, AVELUMAB, PD-1 / PD-L1 monoclonal antibody, Adebrelimab combined with SOX regimen, Pf-06865571, Avelumab (MSB0010718C).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mw032.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

MW032 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MW032 (MW032) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor. Area: Oncology.

phase 3 PD-L1 inhibitor PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MW032 (MW032) — Mabwell (Shanghai) Bioscience Co., Ltd.. MW032 is a monoclonal antibody targeting PD-L1 to enhance anti-tumor immune responses by blocking the interaction between PD-L1 and PD-1/B7-1.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MW032 TARGET	MW032	Mabwell (Shanghai) Bioscience Co., Ltd.	phase 3	PD-L1 inhibitor	PD-L1
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
PD-1 / PD-L1 monoclonal antibody	PD-1 / PD-L1 monoclonal antibody	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	marketed	PD-1/PD-L1 inhibitor	PD-1 and/or PD-L1
Adebrelimab combined with SOX regimen	Adebrelimab combined with SOX regimen	Yang Jianjun, PhD	marketed	PD-L1 inhibitor	PD-L1
Pf-06865571	pf-06865571	Pfizer	marketed	Monoclonal antibody	PD-1/PD-L1 pathway
Avelumab (MSB0010718C)	avelumab-msb0010718c	Pfizer	marketed	Monoclonal antibody	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor class)

Biocad · 13 drugs in this class
Shanghai Henlius Biotech · 8 drugs in this class
Celltrion · 5 drugs in this class
Mabwell (Shanghai) Bioscience Co., Ltd. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 2 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 2 drugs in this class
CStone Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MW032 — Competitive Intelligence Brief. https://druglandscape.com/ci/mw032. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing